Fig. 1.

KBU2046 selectively inhibits cell motility. a Schematic flow of probe synthesis and development strategy. b Cell invasion. Human prostate metastatic cells (PC3, PC3-M), and HPV-transformed normal (1532NPTX, 1542NPTX) and primary cancer (1532CPTX, 1542CPTX) cells, were treated with 10 µM genistein (G), KBU2046 (46), or vehicle (CO), and after 3 days, cell invasion was measured. Values are mean ± SEM of a single experiment in replicates of N = 4, with similar findings in multiple separate experiments (also N = 4). c Single-cell migration. Cell migration was measured after treatment for 3 days with 10 µM KBU2046 or vehicle (control). Values are mean ± SEM of a single experiment in replicates of N = 24, with similar findings in a separate experiment (also N = 24). *Denotes Student’s t-test P value <0.05, compared to controls. d Human cord blood hematopoietic stem cell colony formation assay. Values are the mean ± SD number of total, CFU-GM, CFU-GEMM, or BFU-E colonies at 14 days after treatment with KBU2046, from a single experiment in replicates of N = 2. e Induction of estrogen-responsive genes. Values are the mean ± SD of a single experiment, with similar results seen in a separate experiment, both in replicates of N = 2